site stats

Cingulate therapeutics filing

WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the … WebCINGULATE THERAPEUTICS LLC: TEXAS FOREIGN LIMITED-LIABILITY COMPANY (LLC) WRITE REVIEW: Address: 1901 W. 47th Place, Ste 310 Kansas City, KS 66205: Registered Agent: C T Corporation System: Filing Date: June 06, 2024: File Number: 0803337838: Contact Us About The Company Profile For Cingulate Therapeutics LLC

Cingulate Inc. (CING) 10K Annual Reports & 10Q SEC Filings

WebOct 13, 2024 · Cingulate Therapeutics' IPO date and price. Cingulate is expected to start trading on Oct. 15. The company now plans to raise $40 million by offering 4.4 million … WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... biostatistics summary https://ayscas.net

Home - Cingulate Inc

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate … WebMar 30, 2024 · (a) the Company’s latest annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended December 31, 2024, as filed with the Commission on ... WebFunding. Cingulate Therapeutics has raised a total of $7.6M in funding over 3 rounds. Their latest funding was raised on Jul 11, 2024 from a Venture - Series Unknown round. Cingulate Therapeutics is registered under the ticker NASDAQ:CING . Their stock opened with $6.00 in its Dec 8, 2024 IPO. biostatistics services

SEC FORM D

Category:CING Institutional Ownership and Shareholders - Cingulate Inc …

Tags:Cingulate therapeutics filing

Cingulate therapeutics filing

Cingulate Provides 2024 Clinical Plan for CTx-1301, an …

WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ...

Cingulate therapeutics filing

Did you know?

WebJul 3, 2024 · Cingulate Therapeutics - ‘D/A’ on 7/3/19 - Notice of an Exempt Offering of Securities - Seq. 1 - Amendment to Notice of an Exempt Offering of Securities -- primary_doc.xml/7.8 - Accession Number 0001593151-19-000001 - Filing - SEC WebJun 29, 2024 · The most recently filed 13Fs

WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... WebCingulate General Information. Description. Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery …

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: SUITE 300: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; KANSAS CITY: …

WebFeb 8, 2024 · Cingulate Therapeutics LLC. February 8, 2024, ... (U.S.) and are instrumental for the filing of the New Drug Application to the U.S. Food and Drug Administration (FDA), expected in the second half ...

WebCingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile. … biostatistics summer programWebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a copy... Copy & paste the following URL into the D2 cell: Do you need help with the setup? Let us know at [email protected]. Close. daisy and donald outlineWebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: … daisy and peach wrestlingWebSep 14, 2024 · Cingulate, Inc. ( NASDAQ: CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform … biostatistics summer courseWebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … daisy and the eggWebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: Third Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; Kansas City: … biostatistics tableWebShane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the Chairman and CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization and biotech commercial operations. During his career, he has held positions at Pfizer ... biostatistics summary step 1 the basics usmle